Case comment: the tax regime for foreign-owned entities in Azerbaijan in the pharmaceuticals sector

Foreign-owned entities operating in Azerbaijan's pharmaceuticals sector navigate a tax environment that is neither straightforwardly permissive nor uniformly burdensome — it is stratified, sector-sensitive, and subject to administrative interpretation that can diverge from the plain text of the Azerbaijani Tax Code. In a series of decisions and rulings issued by Azerbaijani tax authorities and courts over the 2024–2027 period, the principal pressure points for foreign pharmaceutical companies have sharpened considerably: VAT treatment of imported medicinal products, withholding tax on cross-border payments to parent entities, and the classification of local subsidiaries as permanent establishments for corporate income tax purposes. Foreign in-house counsel advising entities with Azerbaijani operations will find that the settled assumptions imported from comparable CIS jurisdictions do not always translate.

Azerbaijan is not a member of the Eurasian Economic Union. That single fact has substantive consequences for foreign pharmaceutical companies that structure their regional presence across CIS markets: the EAEU's harmonised VAT regime and its mutual recognition protocols for medicinal products do not extend to Azerbaijani territory. Foreign-owned pharmaceutical entities — whether registered as limited liability companies, joint stock companies, or operating through representative offices — are therefore subject to the Azerbaijani Tax Code as a self-contained framework, without the benefit of supranational alignment that applies in Russia, Kazakhstan, or Armenia.

The pharmaceuticals sector occupies a recognised position within Azerbaijani economic policy. State programmes directed at import substitution and domestic production capacity have created a dual landscape: preferential treatment for entities involved in local manufacture of medicinal products, and standard — or in some cases heightened — scrutiny for entities whose Azerbaijani presence is primarily one of importation and distribution. The tax treatment of foreign-owned entities in the sector is not uniform and depends materially on the economic substance of the Azerbaijani operation, the structure of intercompany arrangements, and the nature of the products involved.

The legal questions that have arisen in administrative and judicial proceedings over the past three years reflect the tension between two competing interests: the Azerbaijani state's appetite for tax base expansion in a commercially significant sector, and the legitimate expectations of foreign investors who entered the market under published incentive frameworks. That tension has not been fully resolved, and the current state of the case law is best described as directional rather than settled.

The administrative and judicial record across the 2024–2027 period reveals three recurring disputes affecting foreign-owned pharmaceutical entities.

The first concerns VAT exemption eligibility for imported medicinal products. Azerbaijani tax legislation provides for VAT relief on a defined list of pharmaceuticals, medical devices, and related inputs. In multiple audit proceedings concluded over this period, the tax authority applied a narrow reading of the exemption list, disallowing relief on composite products — formulations that contain an exempt active ingredient but are presented in a combined or multi-component form not expressly enumerated on the approved list. Foreign entities that had relied on the exemption for such products without seeking advance confirmation from the Ministry of Economy or the relevant pharmaceutical regulator found themselves subject to retrospective VAT assessments, together with associated interest. The courts, in the majority of contested cases reviewed, upheld the authority's narrow reading, though a minority of first-instance decisions adopted a purposive construction favouring the taxpayer — creating a circuit-level inconsistency that remains unresolved at the time of writing.

The second dispute category relates to withholding tax on payments characterised as royalties or service fees remitted to non-resident parent entities or affiliates. Foreign pharmaceutical companies commonly structure their Azerbaijani subsidiaries as licensees of intellectual property — brand rights, formulation patents, regulatory dossiers — held by the parent or a regional IP holding company. The Azerbaijani tax authority has, in a number of cases, challenged the characterisation of such payments, either re-characterising them as dividend distributions (attracting withholding at a different rate) or contesting whether the underlying IP has genuine economic value as deployed in the Azerbaijani market. Where double tax treaty protection is available — Azerbaijan maintains a network of bilateral treaties, including with a number of European jurisdictions — treaty relief has been available in principle but contested in procedure: documentation requirements applied by the authority have been interpreted strictly, and treaty applications submitted without advance residency certification from the counterpart jurisdiction's tax authority have routinely been rejected at first instance.

The third category involves the permanent establishment risk arising from the activities of local employees or agents performing functions beyond the passive maintenance of a representative office. In several proceedings, the tax authority characterised the activities of locally based medical science liaisons, regulatory affairs managers, and clinical development co-ordinators as creating a taxable presence — either as a dependent agent PE or as a service PE — giving rise to corporate income tax exposure on profits attributable to those functions. These characterisations have been contested, with mixed results. The cases that turned in the taxpayer's favour tended to involve strong contemporaneous documentation showing that the local employees operated under detailed central direction and had no authority to conclude or modify contracts.

"The Azerbaijani cases from this period are significant not because they introduce novel legal principles, but because they show an administrative apparatus gaining confidence in applying standard CIS-era tools — PE characterisation, payment re-characterisation, exemption list literalism — to a sector that had previously attracted lighter scrutiny." — Leyla Mammadova, Contributing Regional Analyst — Azerbaijan

[CTA: If your entity holds pharmaceutical assets or distribution rights in Azerbaijan and you are reassessing your intercompany structure or preparing for an audit — make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

For in-house counsel managing a foreign-owned pharmaceutical entity in Azerbaijan, the cases described above carry four practical implications.

First, VAT exemption positions should be reviewed against the current approved list and not assumed to carry forward from prior periods. The approved list is subject to amendment, and the administrative practice of narrow textual interpretation means that composite or reformulated products require fresh analysis. Entities that have historically taken the exemption without documentary confirmation of list membership are exposed in any audit cycle.

Second, intercompany IP licensing arrangements require treaty documentation to be assembled before payments are made, not at the point of audit. The Azerbaijani tax authority's procedural requirements for treaty relief are formal and advance-oriented. Retroactive treaty claims face a materially higher rejection rate than claims supported by pre-payment residency certification. For European parent entities, this typically means engaging with the tax authority in the parent jurisdiction to obtain the requisite confirmation before each payment cycle — a step that adds administrative burden but is not operationally complex if built into the payment calendar.

Third, the PE risk from locally based personnel performing regulatory or commercial functions is live and should be managed through documented governance: job descriptions, escalation protocols, and written confirmation that locally employed staff lack authority to bind the entity contractually. The cases that succeeded at tribunal consistently shared this documentation profile. Those that failed commonly relied on the formal designation of the local entity as a representative office as a proxy for functional limitation — a position the authority no longer accepts without supporting evidence.

Fourth, and more broadly, the direction of Azerbaijani tax enforcement in the pharmaceuticals sector is towards closer alignment with the revenue-maximising approaches applied in the wider CIS region. Entities that entered the Azerbaijani market under an earlier, lighter-touch regime should treat the administrative record of the past three years as a recalibration signal — not a temporary enforcement spike — and adjust their compliance and structuring assumptions accordingly.

For foreign companies operating across the wider South Caucasus and Central Asian region, it is worth noting that comparable analytical frameworks apply in Georgia's tax framework for foreign pharmaceutical entities (/jurisdictions/georgia/tax/), the tax regime for inbound investors in Armenia (/jurisdictions/armenia/tax/), and the Azerbaijani market entry and company formation framework (/jurisdictions/azerbaijan/company-formation/) — each with jurisdiction-specific variation.

[CTA: For in-house counsel managing pharmaceutical operations across CIS or South Caucasus jurisdictions, a cross-jurisdictional tax review can clarify exposure and identify structuring adjustments — make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

• Market entry and company formation in Azerbaijan (/jurisdictions/azerbaijan/company-formation/)
• Corporate structures and joint ventures in Azerbaijan (/jurisdictions/azerbaijan/corporate-jv/)
• Tax advisory for inbound investors in Azerbaijan (/jurisdictions/azerbaijan/tax/)
• Comparative tax regime: Kazakhstan inbound (/jurisdictions/kazakhstan/tax/)
• Asset tracing and recovery — Azerbaijan (/jurisdictions/azerbaijan/asset-recovery/)

Q: What does this series of decisions change for foreign pharmaceutical companies already operating in Azerbaijan?

A: The decisions do not alter the legislative framework — VAT exemption eligibility, withholding tax rates, and PE rules remain as set out in the Azerbaijani Tax Code and applicable bilateral tax treaties. What has changed is the administrative and judicial interpretation of those rules. The tax authority now applies a narrower reading of VAT exemption lists, imposes stricter procedural conditions on treaty relief claims, and is more willing to characterise local employee functions as giving rise to a permanent establishment. Foreign companies that structured their Azerbaijani operations on the basis of an earlier, more permissive interpretive approach should reassess whether that approach remains defensible under current administrative practice.

Q: What should foreign companies do in light of these decisions?

A: Three steps are advisable in the near term. First, review the VAT classification of imported pharmaceutical products against the current approved list, paying particular attention to composite or multi-component formulations. Second, audit the intercompany payment documentation for IP licences and service arrangements, and ensure that treaty residency certificates are obtained in advance of each payment cycle. Third, review the functional analysis of locally employed staff in Azerbaijan and ensure that governance documentation supports the absence of contract-concluding authority. For entities with significant Azerbaijani revenue, external counsel with direct experience of current administrative practice is preferable to reliance on the formal text of the Tax Code alone.

Vetrov & Partners is a boutique law firm established in 2009, recognised by Pravo-300 for eight consecutive years. The firm advises foreign companies and investors on cross-border matters involving Russian and CIS-adjacent legal systems, including tax structuring, regulatory compliance, and dispute resolution.

For inbound matters involving jurisdictions outside the Russian Federation — including Azerbaijan, Georgia, Kazakhstan, and Armenia — the firm collaborates with qualified local counsel and contributing regional analysts, combining Russian practice depth with regional network coverage.

Enquiries: info@vetrovpartners.com | WhatsApp / Telegram: +7 (983) 510-38-76 | t.me/vitvetcom

— Leyla Mammadova Contributing Regional Analyst — Azerbaijan · Energy Sector and Transit Corridor Regulation vetrovpartners.com/contributions/

This publication is provided for informational purposes only and does not constitute legal advice under Russian or any other applicable law. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Vetrov & Partners is a Russian-qualified law firm. For matters governed by foreign law or requiring local admission in another jurisdiction, we collaborate with trusted counsel in the relevant jurisdiction. For advice regarding your particular situation, please contact info@vetrovpartners.com.